DURHAM, N.C. – A more accurate method for measuring blood levels of specialized cells that circulate in the bloodstream and repair damage to the arterial lining has been discovered by Duke University ...
The recently passed federal defense budget for 2026 includes dedicated funding for the use of bioengineered blood vessels ...
– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair – – In clinical testing SYMVESS was ...
19h
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society - - After up to 36 months of follow-up, ...
Clinical Trials Arena on MSN
Artivion’s aortic stents boost post-surgical outcomes in interventional studies
Two of the company’s aortic stents have displayed potential to improve patient outcomes post-surgery.
An aortoenteric fistula is a rare but life threatening complication of aortic surgery requiring immediate surgical repair. Early symptoms include abdominal pain or vomiting blood. A fistula is an ...
An aortocaval fistula is a rare complication of an abdominal aortic aneurysm that requires immediate surgical repair. Doctors can choose to treat it with either open or endovascular surgery. An ...
Stanley’s vascular surgeons successfully perform two complex aortic repairs in a month, showcasing advanced care in Tamil ...
DURHAM, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results